We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Bladder Cancer

Journal Scan / Research · July 21, 2021

An Economic Comparison of Healthcare Resource Use and Cost of ddMVAC and Cisplatin vs Gemcitabine and Cisplatin as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer

Urologic Oncology: Seminars and Original Investigations

 

Additional Info

Urologic Oncology: Seminars and Original Investigations
An Economic Analysis Comparing Health Care Resource Use and Cost of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Versus Gemcitabine and Cisplatin as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
Urol. Oncol 2021 Jun 20;[EPub Ahead of Print], K Montazeri, G Dranitsaris, JD Thomas, C Curran, MA Preston, GS Steele, KL Kilbridge, C Mantia, P Ravi, BA McGregor, M Mossanen, G Sonpavde

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading